• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 18th September 2018

MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?

Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA) initiative, and discuss why it can be beneficial to all parties involved and how…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA) initiative, and discuss why it can be beneficial to all parties involved and how it can improve decision making for – and access to – orphan drugs in European countries.

Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Access (MoCA) initiative, and discuss why it can be beneficial to all parties involved and how it can improve decision making for – and access to – orphan drugs in European countries.

There is considerable variation in the degree and speed of adoption of orphan drugs across European countries. Could a joint European process expedite value assessment and funding decisions for these interventions in individual countries?

MoCA is a voluntary, non-binding, free-of-charge collaboration between stakeholders, created under the European Commission Process on Corporate Responsibility in the Field of Pharmaceuticals. The Medicines Evaluation Committee of the European Social Insurance Platform (MEDEV) initiated MoCA pilots in 2013. The MoCA process and discussions are non-binding, and no recommendations are published. Key benefits of the MoCA process include increased predictability of outcomes of reimbursement processes, effective evidence generation plans (both pre- and post-launch), and sharing of expertise among countries.

So far, 15 companies have participated in pilot projects (see, for example, Hughes-Wilson, 2014) involving a series of multi-country level discussions between national payers, patients (recruited by EURORDIS – Rare Diseases Europe), applicant companies, and experts from the pharmaceutical industry around evidence development and reimbursement schemes. MoCA pilots are bespoke to the needs of the applicant company: there are no set procedures and timelines vary from pilot to pilot.

As part of MoCA, the Transparent Value Framework (TVF) was created to structure a discussion about the value of new orphan drugs, prior to national pricing and reimbursement submissions. The TVF includes four criteria: unmet need, relative effectiveness, response rate and degree of certainty. For each of the four criteria, a product can be scored using a categorical scale with three levels (‘low’, ‘medium’, and ‘high’).

In principle, having a pan-European assessment of new orphan drugs before the start of national pricing and reimbursement processes can be optimal for two reasons. First, the evidence base of orphan drugs near their launch can be limited (in some cases based on phase II trials), therefore it might be more efficient to review it centrally rather than at the individual country level. Second, some countries, particularly the smallest, might not have the required capacity and expertise to conduct an in-depth assessment of orphan drugs, especially those targeting very rare conditions which often affect a few patients in one country. Given the different ability and willingness to pay for health interventions of individual countries, a joint assessment should focus on the clinical benefit, leaving considerations about value for money, affordability, and social values to national processes. This is in line with the recent European Commission proposal on ‘joint clinical assessment’.

However, in the case of orphan drugs, because of the limited pool of patients affected and clinical experts across Europe, there is a case to develop a value framework that could capture a wide range of elements that are relevant to these medicines and the conditions they target. This could structure an early dialogue between key stakeholders at the central level. For any multi-dimensional value framework, a series of steps are required, including agreement on the value dimensions, their definition and their relative importance, and how to combine them.

The TVF is an initial guide to discussing value aspects of a new orphan drug and is not meant to support a quantitative value assessment. However, it has the potential to be further developed to create a valuable tool for national decision making. More work could be conducted to this end, focussing on areas such as:

  • the selection and definition of criteria to allow their separate measurement and ensure they comply with recommended properties such as non-overlap;
  • a method to score the medicine under discussion according to the criteria, potentially more granular than the three-category proposal;
  • a method to weight the various criteria from different perspectives, acknowledging the relative importance of the dimensions of value, while allowing individual countries to use the results to inform further discussions around trade-offs in funding decisions.

Achieving consensus among the members of a multi-country consortium may prove difficult, though recommendations on value frameworks for orphan drugs are available for implementation (see Annemans et al, 2017, for example). For applicant companies, it is advisable to initiate the process at an early stage of the product lifecycle, when designing Phase 3 (or even earlier, for products with adaptive development designs), to inform evidence generation for payers’ submissions and post-launch real-world use. Payers and patients need to weigh the benefits of participating in MoCA at an early stage of product development against the risk of committing resources to discuss a product with considerable uncertainty, including whether the product will reach the market at all.

Related research

Towse, A. and Garau, M. (2018). Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence. OHE Consulting Report. RePEc

Zamora, B., Maignen, F., O’Neill, P., Mestre-Ferrandiz, J. and Garau, M. (2017). Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and Other European Countries. OHE Consulting Report. RePEc

Garau, M. and Devlin, N. (2017). Using MCDA as a decision aid in Health Technology Appraisal for coverage decisions: opportunities, challenges and unresolved questions. In “Multi-Criteria Decision Analysis to Support Healthcare Decisions” Marsh, K., Goetghebeur, M., Thokala, P., Baltussen, R. (Eds.). Springer book. DOI

  • Health Technology Assessment…
  • Value, Affordability, and…
  • EU

Related Insights

HTA Slovak Republic-1
  • Insight
  • September 2023

Around The World in HTAs: The Slovak Republic – Valuing the Future

Read more
European Union flag on the background of old locked doors
  • Insight
  • May 2023

New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives

Read more
Slovak discounting_andrik-langfield-0rTCXZM7Xfo-unsplash_landscape
  • Insight
  • May 2023

Setting the Right Discount Rate for HTA in the Slovak Republic

Read more
Optimise_AdobeStock_576507456_landscape
  • Insight
  • April 2023

How Restrictive are NICE ‘Optimised’ Decisions?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!